AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05873712 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT05873712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study NCT04791943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 MG
Description: 3 melatonin 10mg capsules will be given to the treatment arm
Study NCT04791943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose pill
Description: 3 lactose pills will be provided to the control arm
Study NCT05631678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin; ASK120067
Description: Take ASK120067 tablets orally once on the first day at 160mg in fast condition;Take rifampicin capsules orally once on the days 8 to 17 at 600mg in fast condition, and a combination of 160mg ASk120067 and 600mg rifampicin were administrated on the 15th day in fast condition.
Study NCT05631678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASK120067;itraconazole
Description: Take ASK120067 tablets orally once on the first day at 80mg in fast condition;Take itraconazole capsules orally twice on the days 8 to 13 at 200mg in fed condition, and a combination of 80mg ASK120067 and 200mg itraconazole were administrated on the 11th day in fast condition.
Study NCT05179174 — intervention group
Intervention type: GENETIC
Intervention: blood sample examination
Description: droplet digital PCR in blood sample for research of mutations of GNA11 and GNAQ genes and the following microRNAs: miR - 506-514 cluster, hsamiR - 592 and hsa - miR - 199a - 5p.
Study NCT06358053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRTE7A2-01 TCR-T cell therapy
Description: Drug 1: Fludarabine + Cyclophosphamide Drug 2: Interleukin-2 Drug 3: CRTE7A2-01 TCR-T Cell
Study NCT05197634 — intervention group
Intervention type: OTHER
Intervention: Not Applicable (observation)
Description: Questionnaire
Study NCT05811429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates exercises
Description: 16 sessions for 8 weeks ,per week 2 sessions will be given.
Study NCT05792397 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TwiFlow-Thrombectomy Catheter System
Description: Patients with acute pulmonary embolism and meeting the conditions of this clinical trial will accept the pulmonary embolism removal operation by the novel device named 'TwiFlow-Thrombectomy Catheter System'
Study NCT05270733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subjects will receive ustekinumab for 8 weeks followed by guselkumab or risankizumab for 8 weeks.
Study NCT06456580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Telitacicept
Description: Subcutaneous injection
Study NCT06456580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection
Study NCT06093386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive Transition Support
Description: Participants assigned to the intervention arm will transfer their transition support leadership to a transition team composed of a transition navigator (an advance practice nurse), a nurse navigator (a registered nurse) and a social worker over 2 years to support them through the multiple phases of CMC transitions including guidance, monitoring, planning, care transfer and transfer completion. CMC and their caregivers will be offered support in care planning, receiving funding, and connecting with a primary care provider and adult subspecialists.
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate
Description: Given subcutaneously or as an injection
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin acetate
Description: Given subcutaneously or as an injection
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin acetate
Description: Given subcutaneously or as an injection
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix acetate
Description: Given subcutaneously or as an injection
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Given orally
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given orally
Study NCT05212857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Given orally
Study NCT05212857 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local treatment for primary lesion
Description: Radical prostatectomy to remove prostate primary lesion
Study NCT05212857 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy for primary lesion
Description: Radical radiotherapy for primary lesion
Study NCT05212857 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy for metastatic lesion
Description: Stereotactic body radiation therapy or proton and heavy ion radiation therapy is preferred, which could treat all the lesions at once or treat different lesions in stages.
Study NCT05401396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swimming immediately after eating
Description: After having the last bite of lunch, the participants will swim in the pool with a specific distance.
Study NCT04860908 — intervention group
Intervention type: OTHER
Intervention: no intervention, observation only
Description: no intervention, observation only
Study NCT05419661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Operational Pre-Planning
Description: Using a 3D printer, printing of the patient's aneurysm from the segmented 3D images obtained during the initial assessment and thus allowing a simulation of the embolization procedure. This pre-operative planning (PPO) carried out in real conditions aims to anticipate the possible complications that could be encountered on the same day of treatment.
Study NCT05525078 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-cigarette
Description: Participants will select a Target Switch on which they will stop smoking cigarettes and switch entirely to the e-cigarette product.
Study NCT05525078 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch, Nicotine lozenge
Description: Participants will select a Target Quit Date on which they will stop smoking, using the patches and lozenges provided.
Study NCT06491966 — intervention group
Intervention type: OTHER
Intervention: observation
Description: data collected includes demographic information, clinical outcomes (mortality rate, ICU stay length), inflammatory markers (e.g., IL-2, IL-10, TNF-α), and treatment details (mechanical ventilation, CRRT, ECMO, antibiotics). Culture results, NGS findings, and imaging reports were also documented.
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Oral tablet
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: IV
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Injection
Study NCT05783505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention program
Description: Non-pharmacological interventions combined with goal directed sedation using dexmedetomidine if needed
Study NCT04678882 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study NCT04678882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab SAR231893
Description: Pharmaceutical form: solution for injection Route of administration: subcutaneous (SC)
Study NCT05696938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wonderlab Nicotinamide Drink
Description: Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
Study NCT05696938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ordinary Drink
Description: Participants in this arm will use a bottle of 25ml each time, twice a day, for 2 months.
Study NCT05162157 — intervention group
Intervention type: DEVICE
Intervention: NuvoAir platform
Description: Nuvoair platform, consisting of a bluetooth spirometer, smartphone application and clinical portal
Study NCT04762901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV
Study NCT05245448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tetrandrine
Description: Administered orally
Study NCT05245448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrandrine
Description: Administered orally
Study NCT05245448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT05694143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education Intervention
Description: This intervention is based on the Health Belief Model Theory, which examines the attitudes and beliefs of adolescents with enhanced knowledge and perceived disease risk. As a result, It aims to build on adolescents' skills and behaviours rather than increase their knowledge, beliefs, and relative skills. In order to develop the education program, health promotion experts with a special interest in changing obesity-related behaviours will assist the researcher.~The intervention is specifically designed to help adolescents:~* To know facts, statistics and harmful effects of obesity and overweight.~* To know facts about physical activity and its importance.~* To know facts about a healthy diet and its importance.~* Definition of BMI and calculating the BMI.~* To read the Nutrition Facts label.~* To develop decision-making and self-care education.
Study NCT05694143 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: They will have their regular curriculums and normal physical activity routine
Study NCT05792657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High dosage in-person exercise coaching
Description: High dosage (one hour each week) of in-person exercise coaching by an exercise professional.
Study NCT05792657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medium dosage in-person exercise coaching.
Description: Medium dosage (one hour every other week) of in-person exercise coaching by an exercise professional.
Study NCT05792657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low dosage in-person exercise coaching
Description: Low dosage (one hour every month) of in-person exercise coaching by an exercise professional
Study NCT05883670 — intervention group
Intervention type: DRUG
Intervention: Serplulimab
Description: Serplulimab will be administered by intravenous infusion at a dose of 300mg on Day 1 of each 21-day cycle until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
Study NCT06154278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imdusiran (AB-729)
Description: 60mg subcutaneously, every 8 weeks, for a total of 4 doses
Study NCT05164107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Globe Mapping and Pulsed Field Ablation System (Globe PF System)
Description: During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.
Study NCT05769725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: Serplulimab, 4.5mg/kg solution intravenously for 30 min in first day every 3 weeks. Repeated every 21 days. 21 days for a cycle.
Study NCT05769725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
Study NCT05769725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m\^2 solution intravenously for 1 hour in first day every 3 weeks. Repeated every 21 days, 21 days for a cycle, from second cycle to seventh cycle.
Study NCT05769725 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S1
Description: Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
Study NCT05769725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Tegafur-gimeracil-oteracil potassium: 50mg bid orally in 14 days, followed by 7 days off. Rrepeated every 21 days. 21 days for a cycle.
Study NCT05132933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP trial - Electrical Impedance Tomography
Description: Three different levels of PEEP and two different levels of FiO2 will be tested without changing anything else in the baseline patient ventilation
Study NCT05228626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVIDEX
Description: COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
Study NCT05228626 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: COVIDEX
Description: COVIDEXTm is a prepared plant extract of Zanthoxylum and Warbugia species that is reported to have antiviral agents, one of which berberine with in vitro activity against SARS COV-2, the causative agent for COVID-19 disease. Others constituents in COVIDEX include alkaloids, sponins, reducing sugars and acidic compounds. IT is given either 2 drops nasally plus 6 drops orally or 6 oral drops only of COVIDEXTm three times daily for 7 days.
Study NCT05403684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-volume breastmilk
Description: Preterm infants will be given high-volume breastmilk
Study NCT06054425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Infusion; intravenous
Study NCT04887766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GS300
Description: Gelesis300 hydrogel in gelatin capsules
Study NCT04887766 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT05552833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Participants will undergo 12 weeks of supervised HIIT training (3 times per week). The HIIT protocol will consist of 4x4 min.
Study NCT05479487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluzoparib+Apatinib
Description: Fluzoparib 100mg bid+ Apatinib 375mg qd
Study NCT05479487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluzoparib Monotherapy
Description: Fluzoparib 150mg bid
Study NCT04943029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
Study NCT04943029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Description: Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
Study NCT04943029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
Study NCT04943029 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be done within the 4th-6th week from day 1 cycle 3 of neoadjuvant treatment (4-6 weeks after day 1 of cycle 3)
Study NCT04552418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potato starch
Description: Starting 5-7 days before treatment with dual-ICI, participant will consume 20g of potato starch (Bob's Red Mill®) once a day for 3 days, then increase to 20g twice a day, continuing throughout dual-ICI treatment (total duration approximately 13 weeks).
Study NCT04052139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose naltrexone
Description: 4.5 mg of low dose naltrexone taken once daily for 8 weeks. In week 1, participants will take 4.5mg of naltrexone once daily. In week 2, participants will take 4.5mg of naltrexone once daily, and a placebo capsule twice daily. In weeks 3 through 7, participants will take 1 placebo capsule with 4.5 mg mg of naltrexone once daily, and 2 placebo capsules twice daily. In week 8, in days 1-4 participants will take 4.5 mg of naltrexone with a placebo capsule once daily and 2 placebo capsules twice daily; in days 5-7, participants will take 4.5 mg of naltrexone once daily, and a placebo capsule twice daily.
Study NCT04052139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Dose will begin at 300 mg daily (300 mg qd), in week 2 the dose will be titrated up to 900 mg daily (300 mg tid). In week 3, the dose will be titrated to 1800 mg daily ( 2 capsules of 300 mg tid) and participants will remain on that dose until week 8. In week 8, in days 1-4 participants will take 1800 mg daily (300 mg+300 mg tid); in days 5-7, participants will take 900 mg daily (300 mg of gabapentin three times daily).
Study NCT04052139 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In week 1, participants will take 1 placebo capsule once daily. In week 2, participants will take 1 placebo capsule three times per day. In weeks 3 through 7, 2 placebo capsules three times per day. In week 8, in days 1-4 participants will take 2 placebo capsules three times per day; in days 5-7, participants will take 1 placebo capsule three times per day. The placebo medications will be composed of lactose and will not contain active ingredients.
Study NCT06054425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risankizumab
Description: Infusion; intravenous
Study NCT05624710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB054707
Description: INCB054707 75 mg will be administered orally on Day 1.
Study NCT05579171 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond 755nm Alexandrite Laser
Description: Fractionated picosecond technology has been shown to lead to statistically significant improvement in atrophic, facial acne scars after 4-6 treatment sessions with minimal pain or downtime
Study NCT06162455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO after extubation after surgery for 5 days 2 times a day for 30 min
Study NCT06162455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200- ppm NO
Description: NO will be supplemented at 200-ppm concentration after surgery for 5 days 2 times a day for 30 min
Study NCT06069791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: subcutaneous injection around bilateral greater occipital nerves
Study NCT05207956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral economics strategies
Description: Behavioral economics features designed to increase motivation to collect data and ease of data collection on the electronic platform.
Study NCT05207956 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic platform
Description: Electronic platform to collect data
Study NCT05207956 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic platform
Description: Electronic platform to collect data
Study NCT05166148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session (a)
Description: Eccentric cycling
Study NCT05166148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session (b)
Description: High intensity concentric cycling realized at the same mechanical power output than eccentric cycling
Study NCT05166148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Session (c)
Description: Low intensity concentric cycling realized at the same metabolic demand than eccentric cycling
Study NCT05332535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: serious game based web application education
Description: serious game based web application education for nursing students
Study NCT06234722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Very Low Nicotine Cigarette
Description: Participants will be assigned to one of two investigational cigarette nicotine levels for the duration of the experiment: 0.4mg/g or 15.8mg/g
Study NCT06234722 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Reduced nicotine regulatory environment
Description: In this regulatory environment, participants' usual combustible cigarette will not be available in the Experimental Tobacco Marketplace and only the participants' assigned investigational cigarette will be the only available combustible cigarette.